Smoke Free Sweden: Oral Nicotine Pouches Are Game-changer for Women in Sweden's Smoke-free Success
STRASBOURG, France--(BUSINESS WIRE)--New research from Smoke Free Sweden reveals oral nicotine pouches are a game-changer in Sweden's path to becoming the world's first smoke-free nation – and are driving unprecedented success among women.
'The evidence is crystal clear: nicotine pouches are the most effective way to help smokers – especially women – quit,'
The report, Power in a Pouch, launched today in Strasbourg, shows pouches have been a decisive catalyst in Sweden's public health success – especially for women, who are quitting smoking faster and more effectively than ever.
Since their introduction in 2016, tobacco-free pouches have:
Helped to accelerate the decline in smoking for both genders, with a nearly 200% rise in quit rates among women.
Outperformed all other quit aids; women ranked pouches nearly three times higher than vapes and 56% higher than gum.
Been identified by the research as the preferred quit aid for all ex-smokers for being clean, socially considerate and stigma-free.
Driven a 49% drop in smoking among women, who historically quit at lower rates than men.
'The evidence is crystal clear: nicotine pouches are the most effective way to help smokers – especially women – quit,' said report co-author Dr. Marewa Glover, a behavioural scientist from New Zealand.
'Health data and women's testimonials show pouches are safe, socially acceptable, and fit modern lifestyles. They're pragmatic, effective, and our best hope for a smoke-free future.'
Sweden's harm reduction strategy stands in contrast to restrictive approaches elsewhere. Rather than banning safer products, Sweden embraced them – recognising they are far less harmful than cigarettes.
Sweden's smoking rate is now 5.3%, just above the 5% smoke-free benchmark. Male lung cancer deaths are 61% below the EU average; total cancer deaths, 34% lower.
Report co-author Dr. Delon Human warned that excessive regulation could jeopardise these gains, especially for women.
'Misguided bans are blocking access to products that save lives,' said Dr. Human, leader of Smoke Free Sweden and former Secretary-General of the World Medical Association.
'That's not just bad policy – it's a public health disaster. Women deserve access to the quit aid that works best.'
Dr. Glover added: 'When women can choose clean, stigma-free options, quit rates soar. Denying access means condemning another generation to smoking-related death.
'Policymakers must follow Sweden's lead – or be complicit in preventable deaths on a massive scale.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Scholarships to 85 Students Pursuing Careers in Healthcare
VICTORVILLE, Calif.--(BUSINESS WIRE)--The Dr. Prem Reddy Family Foundation presented $110,000 in academic scholarships to 85 outstanding and diverse High Desert students pursuing careers in health sciences during its annual ceremony Thursday in Victorville. Thursday's event was the latest in the Foundation's decades-long mission to encourage and support the newest generation of healthcare professionals. To date, the Foundation has awarded more than $2 million in scholarships. 'The event was more than a celebration of achievement—it was a tribute to the passion and purpose it takes to pursue a calling in healthcare,' said Sunitha Reddy, Executive Director. 'These scholars are the reason this Foundation exists. Through their commitment to serve, they carry forward a legacy grounded in compassion, access, and hope.' This year's scholarship recipients ranged in age from 16 to 54, including high school students overcoming adversity and single mothers returning to school. A record number of applications were received in 2025, reflecting both increased need and interest in healthcare careers. 'You've chosen a path in healthcare, a path that demands knowledge, compassion, and resilience,' said Sunitha Reddy. 'As you care for others, never forget that your journey is part of a greater legacy, one rooted in service and driven by the belief that every patient deserves to be seen, heard, and healed.' Among the recipients was Tiffany Bogan, who shared her powerful personal journey. Born with neonatal abstinence syndrome and placed in foster care, she later survived Hurricane Katrina and faced continued hardship from addiction and loss in her family. "I'm not here because everything went right—I'm here because I never gave up,' Bogan said. 'I've built this future from the ground up, and I plan to use it to serve others as a doctor, shaped by struggle and led by love." The keynote address was delivered by Karyl James, Chief Nursing Officer at Desert Valley Hospital, who spoke on perseverance, purpose, and service in healthcare. 'As you stand at the crossroads of your journey in healthcare, remember that your path is not just about the destination—it's about the lives you touch, the lessons you learn, and the growth you experience along the way,' she said. Founded in 1989 by Dr. Prem Reddy, Founder, Chairman and CEO of Prime Healthcare, the Foundation supports scholarships, health education, public health programs, and community clinics locally and globally. The list of speakers and presenters included: Sunitha Reddy, MBA, MPH, FACHE, Executive Director of the Dr. Prem Reddy Family Foundation Dr. Venkamma Reddy, Co-Founder of the Dr. Prem Reddy Family Foundation Karyl James, DNP, MSN, RN, Chief Nursing Officer at Desert Valley Hospital Tiffany Bogan, 2025 Dr. Prem Reddy Family Foundation Scholarship recipient Elizabeth Becerra, Mayor, Victorville Representatives and citations from the offices of U.S. Congressman Jay Obernolte, State Senator Suzette Valladares, and Assemblyman Tom Lackey Marie Langley, MBA, FACHE, Chief Executive Officer, Desert Valley Medical Group The High Desert is designated as a Health Professional Shortage Area, with many recipients expressing a commitment to serve locally. To address physician shortages across the Inland Empire, Dr. Reddy and the Foundation helped establish the California University of Science and Medicine (CUSM) with a contribution exceeding $80 million. CUSM graduated its first class of 62 physicians in 2022, many of whom plan to serve the region. About the Dr. Prem Reddy Family Foundation The Dr. Prem Reddy Family Foundation, founded by Dr. Prem Reddy and his family, has donated millions in support of health education, college scholarships, public healthcare education, and free community clinics. On a global level, the foundation supports Samaritan's Purse by donating equipment used in clinics in poverty-stricken regions around the world. The foundation also funds clean water initiatives, childhood vaccinations programs, educational grants, new medical clinics, and medical missions. For more information, visit
Business Wire
3 hours ago
- Business Wire
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year ended March 31, 2025, and provided a corporate update. 'This was a defining year for Vistagen, marked by significant progress in our registration-directed PALISADE program for fasedienol in social anxiety disorder. With over 30 million U.S. adults affected by this serious and life-threatening disorder and no FDA-approved acute treatment, the need is urgent,' said Shawn Singh, President and Chief Executive Officer of Vistagen. 'The enthusiasm from both patients and physicians continues to motivate us as we advance toward our next significant milestone of topline data from our PALISADE-3 trial later this year. We are also continuing to advance the development of our other lead programs, itruvone for major depressive disorder and PH80 for menopausal hot flashes and additional women's health indications. With five novel pherine product candidates in our neuroscience pipeline targeting at least six high-need indications, we are energized by the road ahead and confident in our strategic position and potential to deliver meaningful value to patients and our shareholders.' Clinical-stage Neuroscience Product Candidates Vistagen is developing a broad and diverse pipeline of five clinical-stage intranasal pherine product candidates. Lead Program Highlights Fasedienol for the Acute Treatment of Social Anxiety Disorder (SAD) The U.S. registration-directed PALISADE Program evaluating intranasal fasedienol for the acute treatment of SAD continues to progress. The PALISADE-3 Phase 3 trial remains on track for expected topline data in the fourth quarter of this year. Topline results for the PALISADE-4 Phase 3 trial are expected in the first half of 2026. Vistagen believes either PALISADE-3 or PALISADE-4, if successful, together with the positive results from PALISADE-2 reported in the second half of 2023, may establish substantial evidence of the effectiveness of fasedienol in support of a potential fasedienol New Drug Application (NDA) submission to the U.S. FDA for the acute treatment of SAD. Vistagen also continues to advance its US-registration-directed nonclinical, CMC, and human factors programs for fasedienol. New research presented by Vistagen at the 2025 Anxiety and Depression Association of America Conference shows that SAD, a serious and potentially life-threatening mental health disorder often associated with co-morbidities such as major depressive disorder and suicidal ideation, now affects more than 30 million U.S. adults, with rising prevalence, especially among those aged 18-22. Yet, diagnosis rates have remained stagnant, and treatment rates have decreased. Itruvone for Major Depressive Disorder (MDD) Building on the positive results from a placebo-controlled exploratory Phase 2A clinical study of itruvone in MDD, Vistagen is currently planning for further Phase 2 development of itruvone under its now open U.S. Investigational New Drug Application (IND). Itruvone has the potential to be a novel, non-systemic, stand-alone treatment for MDD without the weight gain, sexual side effects, and safety concerns associated with currently available depression therapies. PH80 for Menopausal Hot Flashes and other Women's Health Indications Building on the positive results from placebo-controlled exploratory Phase 2A clinical studies of PH80 in vasomotor symptoms (hot flashes) due to menopause and premenstrual dysphoric disorder (PMDD), Vistagen is currently preparing its U.S. IND to facilitate further Phase 2 clinical development of PH80 for women's health conditions. Additional Program Highlights PH80 showed efficacy for the treatment of Premenstrual Dysphoric Disorder (PMDD), a condition with limited effective treatment options, in an exploratory Phase 2A trial. PH15 showed potential for improvement of psychomotor impairment caused by mental fatigue in a pilot Phase 2A study. PH284 demonstrated positive results on appetite from an exploratory Phase 2A study in cancer cachexia. Corporate Update Workplace Recognition Recognized for its workplace culture, Vistagen was awarded the highest level of recognition, the Platinum Bell Seal for Workplace Mental Health, from Mental Health America for the third consecutive year. The company was certified by Great Place To Work® for the second year in a row. Financial Results for Fiscal Year Ended March 31, 2025 Research and development (R&D) expenses R&D expenses were $39.4 million and $20.0 million for the fiscal years ended March 31, 2025, and 2024, respectively. The increase in R&D expense was primarily due to an increase in research, clinical and nonclinical development, and contract manufacturing expenses and headcount related to the U.S. registration-directed PALISADE Program for fasedienol in SAD and U.S. IND-enabling program for PH80 in women's health. General and administrative (G&A) expenses G&A expenses were $17.1 million and $14.1 million for the fiscal years ended March 31, 2025, and 2024, respectively. The increase in G&A expense was primarily due to an increase in headcount and consulting and professional services fees. Net loss Net loss was $51.4 million for the year ended March 31, 2025, as compared to $29.4 million for the year ended March 31, 2024. Other financial highlights Cash, cash equivalents and marketable securities were $80.5 million as of March 31, 2025. Conference Call and Webcast: Vistagen will host a conference call and live audio webcast today, June 17, 2025, at 5:00 p.m. Eastern Time to provide a corporate update of Vistagen's progress. The conference call is being webcast live, and a link can be found under 'Events' in the Investors section of Vistagen's website. Participants may register to join the live call by following the link here to receive the dial-in numbers and unique PIN to access the call. Those who plan on participating are advised to join 15 minutes prior to the start time. A webcast replay of the call will be available on Vistagen's website about 24 hours after the end of the live conference call and will be accessible for at least 30 days. About Pherines Vistagen's neuroscience pipeline currently consists of five investigational pherine product candidates, each with a novel mechanism of action (MOA) and positive clinical data in their targeted indications. Pherines are agonists on peripheral receptors in human nasal chemosensory neurons and are designed to rapidly activate nose-to-brain neurocircuits believed to regulate brain areas without requiring systemic absorption or uptake into the brain to achieve desired therapeutic benefits and differentiated safety. About Social Anxiety Disorder Social anxiety disorder (SAD) is a highly prevalent, serious, and sometimes life-threatening psychiatric mental health disorder affecting over 30 million adults in the U.S. With onset typically early in life, usually during adolescence, SAD persists for many years thereafter, with a reported mean duration of about 20 years. While often a long-term disorder, SAD can manifest acutely when triggered by anxiety-provoking social and performance situations during which individuals with SAD experience extreme anxiety, distress, fear, and impairment due to their feelings of embarrassment, judgment, humiliation, negative evaluation, and scrutiny. The disorder can significantly disrupt family and social life, diminish self-esteem, and hinder work performance. Anxiety associated with SAD often results in avoidance of everyday interactions and opportunities in academic, social, and vocational settings and an increased risk of serious and life-threatening co-morbid depression, substance abuse, suicidal ideation, and suicide. About Vistagen Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to rapidly activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. They are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options if successfully developed and approved. Vistagen's neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor. Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, and multiple women's health conditions, including vasomotor symptoms (hot flashes) associated with menopause. Connect at Forward-looking Statements This press release contains certain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve known and unknown risks that are difficult to predict and include all matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of words such as 'may,' 'could,' 'expect,' 'project,' 'outlook,' 'strategy,' 'intend,' 'plan,' 'seek,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'potential,' 'strive,' 'goal,' 'continue,' 'likely,' 'will,' 'would' and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Vistagen and its management, are inherently uncertain. As with all pharmaceutical products, there are substantial risks and uncertainties in the process of development and commercialization, and actual results or developments may differ materially from those projected or implied in these forward-looking statements. There can be no guarantee that any of Vistagen's product candidates will successfully complete ongoing or future clinical trials within estimated timelines or at all, receive regulatory approval or be commercially successful, or that Vistagen will be able to successfully replicate the result of past studies of any of its product candidates. Other factors that may cause such a difference include, without limitation, risks and uncertainties relating to conducting and/or completing ongoing clinical trials, including PALISADE-3 and/or PALISADE-4, as currently expected or at all; completing IND-enabling programs for applicable product candidates, including itruvone and PH80; submission of a new drug application (NDA) to the U.S. FDA for any of Vistagen's product candidate, including fasedienol; the ability of any clinical trial information submitted by Vistagen to the U.S. FDA to support a NDA; Vistagen's dependence on third-party collaborators for the development, regulatory approval, and/or commercialization of its product candidates and other aspects of its business, which are outside of Vistagen's full control; risks and uncertainties resulting from disruptions and personnel turnover, staff reductions or otherwise, at the FDA, other government agencies and comparable foreign regulatory authorities; risks associated with current and potential future healthcare reforms; the scope and enforceability of Vistagen's patents, including patents related to Vistagen's pherine product candidates and AV-101; fluctuating costs of materials and other resources and services required to conduct Vistagen's ongoing and/or planned clinical and non-clinical trials; market conditions; the impact of general economic, industry or political conditions in the United States or internationally; and other technical and unexpected hurdles in the development, manufacture and commercialization of Vistagen's product candidates. These risks are more fully discussed in the section entitled 'Risk Factors' in Vistagen's Annual Report on Form 10-K for the fiscal year ended March 31, 2025, as well as discussions of potential risks, uncertainties, and other important factors in our other filings with the U.S. Securities and Exchange Commission (SEC). Vistagen's SEC filings are available on the SEC's website at You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing Vistagen's views as of any subsequent date. Vistagen explicitly disclaims any obligation to update any forward-looking statements other than as may be required by law. If Vistagen does update one or more forward-looking statements, no inference should be made that Vistagen will make additional updates with respect to those or other forward-looking statements. 2025 2024 ASSETS Current assets: Cash and cash equivalents $ 67,131 $ 119,166 Marketable securities 13,351 — Prepaid expenses and other current assets 1,594 1,506 Total current assets 82,076 120,672 Property and equipment, net 476 435 Right-of-use asset - operating lease 1,335 1,820 Other assets 454 726 Total assets $ 84,341 $ 123,653 LIABILITIES AND STOCKHOLDERS ' EQUITY Current liabilities: Accounts payable $ 653 $ 1,547 Accrued expenses 8,810 2,235 Deferred revenue - current portion 2,588 791 Operating lease liability - current portion 561 550 Total current liabilities 12,612 5,123 Deferred revenue - non-current portion 391 2,674 Operating lease liability - non-current portion 948 1,570 Total liabilities 13,951 9,367 Commitments and contingencies Stockholders' equity: Preferred stock, $0.001 par value; 10,000,000 shares authorized at March 31, 2025 and March 31, 2024; no shares outstanding at March 31, 2025 and March 31, 2024 — — Common stock, $0.001 par value; 325,000,000 shares authorized at March 31, 2025 and March 31, 2024; 29,001,481 and 27,029,731 shares issued at March 31, 2025 and March 31, 2024, respectively 29 27 Additional paid-in capital 481,956 474,441 Treasury stock, at cost, 4,522 shares of common stock held at March 31, 2025 and March 31, 2024 (3,968 ) (3,968 ) Accumulated other comprehensive gain 5 — Accumulated deficit (407,632 ) (356,214 ) Total stockholders' equity 70,390 114,286 Total liabilities and stockholders' equity $ 84,341 $ 123,653 Expand Year Ended March 31, 2025 2024 Revenues: Sublicense and other revenue $ 486 $ 1,064 Total revenues 486 1,064 Operating expenses: Research and development 39,375 20,022 General and administrative 17,084 14,063 Total operating expenses 56,459 34,085 Loss from operations (55,973 ) (33,021 ) Other income, net: Interest income, net 4,557 3,351 Other income, net 5 312 Loss before income taxes (51,411 ) (29,358 ) Income taxes (7 ) (4 ) Net loss $ (51,418 ) $ (29,362 ) Unrealized gain on marketable securities $ 5 $ — Comprehensive loss $ (51,413 ) $ (29,362 ) Basic and diluted net loss per common share $ (1.67 ) $ (1.52 ) Weighted average common shares outstanding, basic and diluted 30,877,029 19,354,500 Expand
Business Wire
4 hours ago
- Business Wire
Materna Medical Announces Ellora™ and Additional Close on $20M Series B2
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Materna Medical, Inc., a leading innovator in women's pelvic health solutions, has announced the completion of a recent close within an ongoing $20 million Series B2 financing round. The round welcomed new funds GLIN Impact Capital, Wealthing VC Club, and Citrine Angels, and was led by InnovaHealth Partners and other key existing investors Wavemaker Three-Sixty Health, Kimera Limited, Women's Venture Capital Fund, and Golden Seeds. "As we celebrate the addition of these new funds to our investment team, we are also excited to announce the new commercial name for our second product, Ellora™ (formerly Materna Prep), aiming to transform the standard of care in labor and delivery," commented Tracy MacNeal, Chief Executive Officer for Materna Medical "Over 20 of the top hospitals in the US have been incredible partners in the EASE trial for Ellora™, which will be the basis of our FDA De Novo submission this summer." For more information on Materna Medical, visit About Materna Medical Materna Medical is a novel OBGYN platform company defining a $25B market with core technologies addressing unmet needs in women's pelvic health. With headquarters in Mountain View, California, Materna pulls from the top minds in MedTech to truly transform the standard of care in OBGYN. With a diverse team of engineers, scientists, researchers, and commercial leaders, Materna Medical's mission is to empower women to protect their pelvic health. Our first product, Milli™, is vaginal dilator to support patients suffering from vaginismus and related painful sex. In 2019, the Milli device launched as a wellness trainer and, in 2023, received FDA clearance to sell over the counter, enabling streamlined access to people suffering from vaginismus. Milli outcomes have been studied in a post-market prospective virtual study named POMPOM. Materna's second product, Ellora™, is an investigational device used during labor and is intended to reduce pelvic floor muscle injury during vaginal delivery. This product is being studied in the EASE trial, a large, randomized controlled trial in 20 top US hospitals. Materna aims to transform the standard of care in labor and delivery by protecting pelvic floor health for moms.
